NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

▤ Summary

NeoGenomics priced a $275 million convertible senior notes offering due 2032, with an option for buyers to purchase additional notes. The company expects net proceeds of about $266.15 million, or more if the option is fully exercised. It plans to use part of the proceeds to fund capped call transactions and repurchase existing convertible notes due 2028, with any remaining funds going to general corporate purposes. The transaction also includes privately negotiated note repurchases and potential stock buybacks tied to the financing structure. NeoGenomics operates in oncology diagnostics and life sciences, so the announcement is relevant to software and healthcare technology audiences only indirectly through its healthtech context.

$ Funding

▦ Linked Companies